Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study

Pediatric Blood & Cancer
Matthew F GormanMignon L Loh

Abstract

Current event-free survival (EFS) rates for children with newly diagnosed acute myeloid leukemia (AML) approach 50-60%. We hypothesize that further improvements in survival are unlikely to be achieved with traditional approaches such as dose intensive chemotherapy or hematopoietic stem cell transplants, since these therapies have been rigorously explored in clinical trials. This report highlights efforts to assess the response rates and survival outcomes after first or greater relapse in children with AML. We performed a retrospective cohort review of pediatric patients with relapsed and refractory AML (rAML) previously treated at TACL institutions between the years of 1995 and 2004. Data regarding disease characteristics at diagnosis and relapse, treatment response, and survival was collected on 99 patients and 164 medullary relapses or treatment failures. The complete response (CR) rate following the second therapeutic attempt was 56 +/- 5%. CR rates following a third treatment attempt was 25 +/- 8% while 17 +/- 7% achieved CR following the fourth through sixth treatments. The 5-year disease-free survival in patients achieving CR following a second therapeutic attempt was 43 +/- 7%. The 5-year EFS and overall survival (OS) ra...Continue Reading

References

Oct 1, 1989·Statistics in Medicine·M Nurminen
Jan 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M E NesbitP F Coccia
Oct 16, 1999·British Journal of Haematology·D K Webb
Jul 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J WellsUNKNOWN Children's Cancer Group Study 2951
Dec 4, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nathalie AladjidiUNKNOWN French Society of Pediatric Hematology and Immunology
Oct 20, 2004·British Journal of Haematology·C M Zwaan, G J L Kaspers
Oct 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Juan J OrtegaUNKNOWN PETHEMA Group
Aug 17, 2006·Blood·Soheil MeshinchiJerald P Radich
Feb 6, 2007·British Journal of Haematology·Jonas AbrahamssonUNKNOWN Nordic Society for Paediatric Haematology and Oncology (NOPHO)
Apr 5, 2007·The Oncologist·Soheil Meshinchi, Robert J Arceci
May 29, 2008·Current Treatment Options in Oncology·Jeffrey E Rubnitz
Sep 2, 2008·The Lancet Oncology·L Charles BaileyNancy J Bunin

❮ Previous
Next ❯

Citations

Apr 9, 2013·Leukemia·A S MooreC M Zwaan
Oct 26, 2013·Paediatric Drugs·Jennifer DavilaThomas Renaud
Jun 26, 2014·International Journal of Hematology·Hideki NakayamaSouichi Adachi
Apr 9, 2013·Memo·Walentyna BalwierzAngelina Moryl-Bujakowska
Dec 10, 2015·Pediatrics International : Official Journal of the Japan Pediatric Society·Takashi TagaSouichi Adachi
Sep 13, 2012·British Journal of Haematology·Jeffrey E Rubnitz, Hiroto Inaba
Jan 21, 2014·Pediatric Blood & Cancer·Stacey MarjerrisonLillian Sung
May 20, 2014·British Journal of Haematology·Gertjan Kaspers
Aug 27, 2015·Endocrine-related Cancer·Maria Isabel C Vieira CordioliJanete M Cerutti
Feb 14, 2015·Cancer·Weili SunAlan S Wayne
Jan 29, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Wei-Ping ZhangJian-Min Wang
Dec 3, 2014·Blood Reviews·L ZhangC Metayer
May 26, 2016·British Journal of Haematology·Paul S Gaynon, Weili Sun
Jul 13, 2016·Molecular Therapy : the Journal of the American Society of Gene Therapy·Challice L BonifantStephen Gottschalk
Apr 27, 2012·Advances in Hematology·Kenneth A FoonPier L Zinzani
Jan 16, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gertjan J L KaspersUrsula Creutzig
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C Michel ZwaanGertjan J L Kaspers
Dec 20, 2011·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Umberto BanderaliAru Narendran
Aug 3, 2017·Medicine·Weijing LiZhigang Li
Dec 27, 2018·Current Opinion in Pediatrics·Agne Taraseviciute, Michael A Pulsipher
Aug 5, 2017·Pediatrics International : Official Journal of the Japan Pediatric Society·Hideki NakayamaSouichi Adachi
Oct 28, 2019·Oncotarget·Amanda M SmithAndrew S Moore
Sep 6, 2018·European Archives of Oto-rhino-laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·Jun TaiXin Ni
Dec 1, 2017·Pediatric Hematology and Oncology·Kara L DavisAnupam R Verma
Dec 7, 2018·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Omima MustafaWasil Jastaniah
Mar 14, 2019·International Journal of Hematologic Oncology·Larisa BroglieMichael J Burke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.